Full-Time
Market Development Manager Interventional Cardiology
Benelux & Nordics
Updated on 2/17/2025
Penumbra Inc
1,001-5,000 employees
Develops medical devices for vascular conditions
Senior
Company Historically Provides H1B Sponsorship
Remote in UK
Position covers UK/Ireland, Benelux, and Nordics regions.
You match the following Penumbra Inc's candidate preferences
Employers are more likely to interview you if you match these preferences:
- Completed education or degree in medicine, natural sciences, biomedical engineering or business administration.
- Several years of interventional sales experience with a strong focus on achieving results.
- Proven experience in the medical device industry, with a background in Interventional Cardiology, preferably related to Coronary Intervention.
- Solid understanding of the hospital environment.
- Enthusiasm, persuasive skills, and readiness to negotiate.
- Excellent communication and presentation skills.
- High willingness to learn, flexibility, and strong commitment.
- Independent working style and reliability.
- Fluency in English, both written and spoken.
- Willingness to travel extensively within UK/Ireland, Benelux & Nordics region.
- Acquiring, establishing, and developing new customers in the hospital sector.
- Managing, advising, and expanding relationships with existing customers.
- Providing application support for Penumbra products to interventional cardiologists.
- Executing all sales-related activities for new product launches and conducting presentations for users and procurement teams.
- Maintaining relationships with key decision-makers on the customer side and market influencers.
- Conducting territory analysis and strategic account planning.
- Implementing sales and marketing strategies.
- Being available to accompany procedures when necessary.
- Participating in regional trade shows and conferences.
- Collaborating closely with internal teams and marketing departments.
- Exchanging knowledge and collaborating across borders with our European team.
Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. What sets Penumbra apart from competitors is their commitment to continuous research and development, ensuring their devices meet the changing needs of the medical field. The company's goal is to provide effective, high-quality medical solutions that improve patient outcomes in neurovascular and peripheral vascular care.
Company Size
1,001-5,000
Company Stage
IPO
Total Funding
$116.7K
Headquarters
Alameda, California
Founded
2004
Simplify's Take
What believers are saying
- The neurovascular devices market is projected to grow at a CAGR of 8.5% until 2030.
- Penumbra's expansion in Costa Rica could reduce production costs and improve efficiency.
- Technological advancements in clot retrieval devices enhance treatment outcomes for ischemic stroke.
What critics are saying
- Don Kassing's retirement may lead to a gap in leadership and strategic guidance.
- Operational challenges in Costa Rica could impact supply chain efficiency and product availability.
- The Italian government's payback provision has already impacted financial results.
What makes Penumbra Inc unique
- Penumbra offers a comprehensive range of neuro and peripheral vascular devices.
- The company focuses on innovative solutions for stroke and neurovascular disease treatment.
- Penumbra's global presence spans North and South America, Europe, Australia, and Asia.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Paid Vacation
Paid Sick Leave
Paid Holidays
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%ALAMEDA, Calif., Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. Kassing joined Penumbra's Board of Directors in 2008 and has served as Presiding Director since 2015."We are grateful for Don's many contributions to the board over the years, particularly his wisdom and guidance in complex situations and through our phases of growth," said Adam Elsesser, board chair, president and chief executive officer of Penumbra. "We also thank Don for his steadfast leadership and dedication to helping Penumbra advance our mission of helping more and more people over the years."Mr. Kassing is President Emeritus of San Jose State University
Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.
ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023
ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity
The Society of Interventional Radiology (SIR) Foundation, The VIVA Foundation and Penumbra, today announced the launch of the EMBOLIZE trial, a first-of-its-kind prospective, randomised controlled trial studying the effects of ovarian vein embolization (OVE) and pelvic vein embolization in reducing pain in women experiencing chronic pelvic pain due to pelvic venous disease (PeVD).